DAXX and sarcoma: Collectively, these results suggest that alterations of ATRX preferentially target its enzymatic functions rather than its protein-protein interactions, thus explaining why mutations in ATRX partner genes (i.e., DAXX, EZH2, SP100) are not frequent and not an alternative to ATRX alteration in sarcomas.